STAT3 and neoplasm: Several studies employing genetic and pharmacological approaches to modulate constitutive signal transducer and activator of transcription 3 (STAT3) activity have substantiated the critical role of aberrant STAT3 activity in malignant transformation and tumor progression, and hence endorse STAT3 as a novel cancer drug target [21].